Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for XRPD Method for Polymorph Characterization – V 2.0

Posted on By

Analytical Method Development: SOP for XRPD Method for Polymorph Characterization – V 2.0

Standard Operating Procedure for XRPD Method Development in Polymorph Characterization


Department Analytical Method Development
SOP No. SOP/AMD/174/2025
Supersedes SOP/AMD/174/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

To establish a detailed procedure for the development and validation of X-ray Powder Diffraction (XRPD) methods used in the identification, confirmation, and characterization of polymorphic forms in pharmaceutical substances.

2. Scope

This SOP is applicable

to the Analytical Method Development (AMD) department for characterization of APIs and formulations, especially for confirming crystal structure, phase purity, and polymorphic transformation during stability and manufacturing processes.

3. Responsibilities

  • Analytical Scientist: Plans and executes XRPD experiments, data interpretation, and documentation.
  • Instrument Operator: Calibrates, aligns, and operates XRPD instrument as per method parameters.
  • QA Officer: Reviews analytical reports and validation data to ensure GMP compliance.
  • Head – AMD: Approves method validation and ensures regulatory readiness of XRPD characterization data.
See also  Analytical Method Development: SOP for Intermediate Precision Evaluation - V 2.0

4. Accountability

The Head of AMD is accountable for the integrity and scientific validity of XRPD methods used in regulatory submissions, product development, and quality assurance.

5. Procedure

5.1 Instrument Calibration

  1. Perform daily calibration using certified silicon or corundum standard.
  2. Verify peak positions and intensities with acceptance criteria (±0.2° 2θ shift).
  3. Record in Annexure-1: XRPD Calibration Log.

5.2 Sample Preparation

  1. Grind sample uniformly using mortar and pestle if needed; avoid over-grinding.
  2. Spread sample evenly on zero-background sample holder (glass or quartz-based).
  3. Level surface to prevent diffraction anomalies.

5.3 Method Parameters

  1. Instrument Settings:
    • Radiation: Cu-Kα (λ = 1.5418 Å)
    • Voltage/Current: 40 kV / 30 mA
    • Scan Range: 2θ = 3° to 40°
    • Step Size: 0.02°
    • Scan Speed: 1.0°/min
  2. Collect diffraction patterns for each sample in triplicate.
  3. Use internal standard (e.g., NaCl) for peak alignment verification if required.
See also  Analytical Method Development: Preparation of Reagents and Volumetric Solutions - V 2.0

5.4 Data Interpretation

  1. Compare peak positions and intensities to reference library (e.g., PDF from ICDD).
  2. Match pattern to polymorphic forms identified during development.
  3. Overlay reference patterns with test sample using XRPD software (e.g., HighScore Plus).
  4. Document in Annexure-2: Diffraction Pattern Record.

5.5 Method Validation

  1. Validate per ICH Q2(R2) and internal quality protocols:
    • Specificity – Confirm unique diffraction peaks of polymorphs
    • Precision – Reproducibility of peak position (RSD ≤ 0.2%)
    • Robustness – Scan rate and sample holder variation
    • Detection Limit – Minimum crystallinity detectable
  2. Record results in Annexure-3: Validation Summary Sheet.

5.6 Application Examples

  1. Identification of polymorphic form in new API batch.
  2. Comparison of reference and stress-tested material for phase transition.
  3. Monitoring batch-to-batch crystal form consistency during scale-up.

6. Abbreviations

  • XRPD: X-ray Powder Diffraction
  • API: Active Pharmaceutical Ingredient
  • RSD: Relative Standard Deviation
  • PDF: Powder Diffraction File
  • ICDD: International Centre for Diffraction Data
  • SOP: Standard Operating Procedure

7. Documents

  1. XRPD Calibration Log – Annexure-1
  2. Diffraction Pattern Record – Annexure-2
  3. Validation Summary Sheet – Annexure-3
See also  Analytical Method Development: Complexometric Titration Method Development - V 2.0

8. References

  • ICH Q2(R2) – Validation of Analytical Procedures
  • USP <941> – X-ray Powder Diffraction
  • European Pharmacopoeia 2.2.33 – XRPD
  • ICDD PDF-4+ Database

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: XRPD Calibration Log

Standard Material Theoretical 2θ (°) Observed 2θ (°) Δ (°) Analyst
Silicon 28.44 28.43 0.01 Rajesh Kumar

Annexure-2: Diffraction Pattern Record

Sample ID 2θ Range Major Peaks (°2θ) Match Reference Analyst
API-XP-109 3–40 11.2, 14.6, 21.7 Polymorph-II Sunita Reddy

Annexure-3: Validation Summary Sheet

Parameter Result Acceptance Criteria Status
Precision RSD = 0.13% ≤ 0.2% Pass
Peak Match Score 98.6% ≥ 95% Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded validation parameters and included polymorph tracking log Annual SOP Review
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for Risk Assessment in Upstream Failures – V 2.0
Next Post: Creams: SOP for Establishing Quality Metrics in Cream Manufacturing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version